Nicotine is a substance with strong addictive potential, whose neurobiological impact is analogous to the dependence caused by cocaine and heroin. Despite the fact that 70% of smokers express a readiness to quit, the annual abstinence rate does not exceed 10% due to the low efficacy of standard therapeutic interventions (nicotine replacement therapy, varenicline).<\/p>\n
This reality highlights the need for the development of new, more effective pharmacological and psychotherapeutic approaches, where the use of psilocybin is considered one of the promising directions.<\/p>\n
The therapeutic effect of psilocybin is based not on the temporary suppression of nicotine withdrawal symptoms, but on the functional transformation of the brain through the stimulation of neuroplasticity. A 2023 study conducted by neuroscientist G\u00fcl D\u00f6len (University of California, Berkeley) confirmed that psychedelics can reopen “critical periods” in the brain. This is a phase of high neuronal flexibility that is typically active only during childhood and helps the individual acquire new behavioral models.<\/p>\n
Psilocybin (the main psychoactive substance in “magic mushrooms”), by acting on specific receptors, temporarily alters the functioning of neural networks responsible for addictive habits. Thus, the brain is liberated from addictive rigidity, allowing psychotherapy to effectively instill new, healthy habits.<\/p>\n
Clinical evidence partially confirms these findings. In a 2017 randomized controlled trial conducted by Johns Hopkins University, the use of a high dose of psilocybin (approximately 30 mg\/70 kg) alongside intensive psychotherapy showed a 52% abstinence rate at a six-month follow-up. For comparison, the success rate in the control group, which used nicotine patches and therapy, was only 25%.<\/p>\n
Additionally, in early pilot studies involving a 15-week structured therapeutic protocol, approximately 80% of participants maintained abstinence over the following six months, significantly outperforming the results of standard pharmacotherapeutic methods, including the average efficacy of varenicline.<\/p>\n
Along with biological and clinical efficacy, a fundamental component of therapeutic success is the phenomenological reconstruction of the individual’s value system. The intensity of the subjective experience induced by psilocybin often exceeds the power of nicotine dependence, leading to a functional devaluation of the addictive behavior. Study participants described such a fundamental change in self-perception that tobacco use lost its subjective meaning and no longer aligned with their personal identity. It is precisely this “cognitive shift” that ensures the sustainability of behavioral change\u2014instead of battling with willpower, the individual undergoes an internal transformation where smoking is perceived as an alien element, incompatible with their new identity.<\/p>\n
Research into the medical potential of psychedelics began as early as the last century. In the 1950s, LSD was successfully used to treat alcoholism; however, the “war on drugs” that began in the 1970s halted research for decades.<\/p>\n
Today, the high scientific interest in psychedelics\u2014the so-called “psychedelic renaissance”\u2014is driven by the accumulation of new empirical data. The renewal of research is directly linked to the fact that over the past 20-30 years, pharmacotherapy has failed to develop sufficiently effective methods for treating addiction and depression. Consequently, re-evaluating the therapeutic potential of psychedelics has become a priority for modern medicine.<\/p>\n
Existing evidence unequivocally indicates that psilocybin-based therapeutic approaches could become an innovative tool in managing nicotine dependence. Despite promising results, the widespread clinical use of psilocybin therapy requires additional validation. It is essential to conduct large-scale studies in more diversified populations to objectively assess the method’s efficacy, safety, and long-term outcomes. A detailed analysis of side effects and risk profiles across various socio-demographic groups is also necessary. In the global context of public health, integrating such interventions could make a decisive contribution to reducing the burden caused by tobacco use and improving population health.<\/p>\n